Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib

Kantarjian, 2004, High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukaemia, Blood, 103, 2873, 10.1182/blood-2003-11-3800 Kantarjian, 2003, Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia, Blood, 101, 473, 10.1182/blood-2002-05-1451 Talpaz, 2002, Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study, Blood, 99, 1928, 10.1182/blood.V99.6.1928 Han, 1998, Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity, Proc Natl Acad Sci USA, 95, 5357, 10.1073/pnas.95.9.5357 Rovera, 1979, Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester, Proc Natl Acad Sci USA, 76, 2779, 10.1073/pnas.76.6.2779 Koeffler, 1980, Phorbol diester-induced macrophage differentiation of leukemic blasts from patients with human myelogenous leukemia, J Clin Invest, 66, 1101, 10.1172/JCI109939 Graham, 2002, Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro, Blood, 99, 319, 10.1182/blood.V99.1.319 Fang, 2005, Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics, Blood, 105, 2733, 10.1182/blood-2004-07-2514